Literature DB >> 15610401

Clinical and immunological effects of azithromycin in Behçet's disease.

G Mumcu1, T Ergun, Y Elbir, E Eksioglu-Demiralp, S Yavuz, T Atalay, H Direskeneli.   

Abstract

BACKGROUND: The aim of this study was to evaluate the effects of azithromycin on mucocutaneous manifestations, oral health and immune response in Behçet's disease (BD).
METHODS: Eight BD patients with active mucocutaneous symptoms were treated with azithromycin for 4 weeks. Oral health, clinical manifestations and in vitro interleukin (IL)-12, interferon (IFN)-gamma, IL-10 and monocyte chemotactic protein (MCP)-1 responses were evaluated before and after treatment.
RESULTS: The number of folliculitic lesions, healing time of oral ulcers and scores of plaque indexes (PLIs) were lower after azithromycin treatment (P<0.05). Scores of PLIs correlated positively with the healing time of oral ulcers (P=0.02). Although a trend towards increased stimulated IL-10 responses with azithromycin was observed, no statistically significant difference was found. Stimulated and unstimulated MCP-1, IFN-gamma and IL-12 responses were similar before and after treatment (P>0.05).
CONCLUSION: Azithromycin was observed to be effective in decreasing folliculitic lesions and fastening the healing time of oral ulcers in BD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15610401     DOI: 10.1111/j.1600-0714.2004.00265.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  7 in total

Review 1.  Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease.

Authors:  Noboru Suzuki; Kazuhiko Nara; Tomoko Suzuki
Journal:  Clin Med Res       Date:  2006-06

2.  Promoter -2518 single nucleotide polymorphism of monocyte chemoattractant protein-1 is associated with clinical severity in Behçet's disease.

Authors:  Seong-Kyu Kim; Won-Cheoul Jang; Young-Chang Ahn; Sang-Hyun Lee; Shin-Seok Lee; Jin-Wuk Hur
Journal:  Inflamm Res       Date:  2012-04-03       Impact factor: 4.575

Review 3.  Recurrent Aphthous Stomatitis: Treatment and Management.

Authors:  Marco Manfredini; Stefania Guida; Matteo Giovani; Nicola Lippolis; Enrico Spinas; Francesca Farnetani; Annunziata Dattola; Eleonora Di Matteo; Giovanni Pellacani; Luca Giannetti
Journal:  Dermatol Pract Concept       Date:  2021-09-01

4.  Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers.

Authors:  Fatma Alibaz-Oner; Gonca Mumcu; Zeynep Kubilay; Gulsen Ozen; Gulce Celik; Aslı Karadeniz; Meryem Can; Sibel Yilmaz Oner; Nevsun Inanc; Pamir Atagunduz; Tulin Ergun; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2014-04-16       Impact factor: 2.980

Review 5.  Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.

Authors:  Cinzia Rotondo; Giuseppe Lopalco; Florenzo Iannone; Antonio Vitale; Rosaria Talarico; Mauro Galeazzi; Giovanni Lapadula; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2015-06-22       Impact factor: 4.711

6.  The oral mucosal and salivary microbial community of Behçet's syndrome and recurrent aphthous stomatitis.

Authors:  Noha Seoudi; Lesley A Bergmeier; Francis Drobniewski; Bruce Paster; Farida Fortune
Journal:  J Oral Microbiol       Date:  2015-06-01       Impact factor: 5.474

Review 7.  Oral Health and Its Aetiological Role in Behçet's Disease.

Authors:  Gonca Mumcu; Farida Fortune
Journal:  Front Med (Lausanne)       Date:  2021-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.